Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Impaired recovery of Epstein-Barr virus (EBV)—specific CD8 + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease

Pauline Meij, Joost W. J. van Esser, Hubert G. M. Niesters, Debbie van Baarle, Frank Miedema, Neil Blake, Alan B. Rickinson, Ingrid Leiner, Eric Pamer, Bob Löwenberg, Jan J. Cornelissen, Jan W. Gratama

Blood (2003) 101 (11): 4290–4297.

https://doi.org/10.1182/blood-2002-10-3001

Published: 2003

Journal Articles

Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

Joost W. J. van Esser, Hubert G. M. Niesters, Bronno van der Holt, Ellen Meijer, Albert D. M. E. Osterhaus, Jan Willem Gratama, Leo F. Verdonck, Bob Löwenberg, Jan J. Cornelissen

Blood (2002) 99 (12): 4364–4369.

https://doi.org/10.1182/blood.V99.12.4364

Published: 2002

Journal Articles

Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8 + T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Jan W. Gratama, Joost W. J. van Esser, Cor H. J. Lamers, Claire Tournay, Bob Löwenberg, Reinder L. H. Bolhuis, Jan J. Cornelissen

Blood (2001) 98 (5): 1358–1364.

https://doi.org/10.1182/blood.V98.5.1358

Published: 2001

Journal Articles

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT

Joost W. J. van Esser, Bronno van der Holt, Ellen Meijer, Hubert G. M. Niesters, Rudolf Trenschel, Steven F. T. Thijsen, Anton M. van Loon, Francesco Frassoni, Andrea Bacigalupo, Ulrich W. Schaefer, Albert D. M. E. Osterhaus, Jan Willem Gratama, Bob Löwenberg, Leo F. Verdonck, Jan J. Cornelissen

Blood (2001) 98 (4): 972–978.

https://doi.org/10.1182/blood.V98.4.972

Published: 2001

Journal Articles

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation

Annoek E. C. Broers, Ron van der Holt, Joost W. J. van Esser, Jan-Willem Gratama, Sonja Henzen-Logmans, Vibeke Kuenen-Boumeester, Bob Löwenberg, Jan J. Cornelissen

Blood (2000) 95 (7): 2240–2245.

https://doi.org/10.1182/blood.V95.7.2240

Published: 2000

NARROW

Impaired recovery of Epstein-Barr virus (EBV)—specific CD8 + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease

Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8 + T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Impaired recovery of Epstein-Barr virus (EBV)—specific CD8 + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease

Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8 + T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only